Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
María‐Victoria Mateos(Instituto de Investigación Biomédica de Salamanca), Michèle Cavo, Joan Bladé(Hospital Clínic de Barcelona), Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Kenshi Suzuki(Japanese Red Cross Medical Center), Andrzej Jakubowiak(University of Chicago Medical Center), Stefan Knop, Chantal Doyen(UCLouvain), Paulo Lúcio(Champalimaud Foundation), Zsolt Nagy(Semmelweis University), Luděk Pour(University Hospital Brno), Mark Cook(University Hospitals Birmingham NHS Foundation Trust), Sebastian Grosicki(Medical University of Silesia), Andre H Crepaldi, Anna Marina Liberati(Azienda Ospedaliera S.Maria), Philip Campbell, Tatiana Shelekhova(Saratov Research Institute of Traumatology and Orthopedics), Sung‐Soo Yoon(Seoul National University), Genadi Iosava, Tomoaki Fujisaki(Matsuyama Red Cross Hospital), Mamta Garg(Leicester Royal Infirmary), Maria Krevvata(Janssen (United States)), Ying Chen(Janssen (United States)), Jianping Wang(Janssen (United States)), Anupa Kudva(Janssen (United States)), Jon Ukropec(Janssen (United States)), Susan Wróblewski(Janssen (United States)), Ming Qi(Janssen (United States)), Rachel Kobos(Janssen (United States)), Jesús F. San Miguel(Navarre Institute of Health Research)
Cited by 438Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis